NCT04904120
- Conditions
- Disease, Eye Diseases, Eye Neoplasms, +23 more
- Locations
-
- Mayo Clinic Rochester, Minnesota, United States
Clinical trial condition
Melanoma Stage IV
Explore clinical trials studying Melanoma Stage IV. Study availability and eligibility vary by location and protocol.
42 public trials
22 recruiting studies
Melanoma Stage IV trial results
NCT04154163
- Conditions
- Adnexal Diseases, Bronchial Neoplasms, Carcinoma, Bronchogenic, +41 more
- Locations
-
- NHS Tayside and University of Dundee Dundee, Scotland, United Kingdom
Active, Not Recruiting
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
NCT04305145
- Conditions
- Chemically-Induced Disorders, Colitis, Colonic Diseases, +24 more
- Locations
-
- Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
Active, Not Recruiting
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
NCT04990726
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Melanoma Stage IV, +17 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279
- Conditions
- Astrocytoma, Brain Cancer, Brain Diseases, +43 more
- Locations
-
- University of California, San Francisco San Francisco, California, United States
- Sarah Cannon Research Institute Denver, Colorado, United States
- Northwestern Medicine Cancer Centers Warrenville, Illinois, United States
- START Midwest Grand Rapids, Michigan, United States
Active, Not Recruiting
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
NCT03161431
- Conditions
- Melanoma, Melanoma Stage III, Melanoma Stage IV, +11 more
- Locations
-
- University of Miami Miami, Florida, United States
- Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
- Mayo Clinic Rochester, Minnesota, United States
Active, Not Recruiting
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
NCT04079166
- Conditions
- Malignant Melanoma, Melanoma, Melanoma (Skin), +13 more
- Locations
-
- Cambridge University Hospitals NHS Foundation Trust Cambridge, United Kingdom
- Velindre University NHS Trust Cardiff, United Kingdom
- The Leeds Teaching Hospitals NHS Trust Leeds, United Kingdom
- Guy's & St Thomas' NHS Foundation Trust London, United Kingdom
Active, Not Recruiting
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
NCT04139902
- Conditions
- Melanoma, Melanoma Stage III, Melanoma Stage IV, +11 more
- Locations
-
- Georgetown University Medical Center Washington D.C., District of Columbia, United States
- Massachusetts General Hospital Boston, Massachusetts, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States
- UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, United States
Active, Not Recruiting
Intrathecal Double Checkpoint Inhibition
NCT05598853
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +25 more
- Locations
-
- University Hospital Zurich Zurich, Canton of Zurich, Switzerland
- University Hospital Basel Basel, Switzerland
- University Hospital Geneva Geneva, Switzerland
Active, Not Recruiting
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
NCT05309421
- Conditions
- Melanoma, Melanoma Stage IV, Neoplasms, +11 more
- Locations
-
- Melanoma Institute Australia Wollstonecraft, New South Wales, Australia
- One Clinical Research Nedlands, Western Australia, Australia
- Divisione di Oncologia Medica del Melanoma Milan, Italy
- Instituto Nazionale Tumori IRCCS Fondazione Naples, Italy